AYTU AYTU BIOPHARMA, INC

Overview and Growth

In fiscal 2026, AYTU BIOPHARMA, INC recorded $57.57M of revenue, net loss of $14.25M, and an operating cash inflow of $3.28M. At $57.57M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Revenue was 13.3% below fiscal 2025 revenue of $66.38M, marking a top-line contraction. At period end, total assets were $105.01M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.55x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Gross profit was $36.82M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 64.0% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $8.31M, reflecting costs that exceeded gross profit. An operating margin of -14.4% reflected costs exceeding revenue-level gross profit by 14.4% of sales. The company ended the period with a net loss of $14.25M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 24.8% after all recognized items. The pretax result was a loss of $14.23M, establishing the deficit before tax effects. Pretax margin was -24.7%, reflecting a pre-tax loss equal to 24.7% of revenue. The company recognized $21.00K of income tax for the period, completing the transition from pretax income to net income. Relative to period-end equity, the net loss represented 40.4%. The net loss equaled 13.6% of period-end assets, showing the deficit relative to the asset base.

Liquidity and Capital Structure

At period end, the $105.01M asset base was financed through $69.73M of liabilities and $35.27M of equity. The near-term balance sheet paired $61.76M of current assets with $54.66M of current liabilities at the reporting date. At 1.13x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $26.31M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 48.1%, excluding receivables and other current assets. Total debt was $10.96M, establishing the amount of borrowing carried within the company’s capital structure. Debt equaled 0.31x of book equity, describing the relative scale of borrowing and shareholder capital. Relative to total assets, debt measured 10.4%, showing how much of the asset base was matched by borrowing. Liabilities represented 66.4% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 25.1% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $124.18M in fiscal 2025, the current asset base moved 15.4% and finished lower. Book equity was 86.0% higher than fiscal 2025 equity of $18.97M, showing how shareholder capital changed year over year.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $3.28M, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. Capital spending was $29.00K, absorbing part of the cash generated from operations before free cash flow. Relative to operating cash flow, capital expenditures measured 0.9%, connecting investment intensity with the company’s cash-generation base. The combination of operating cash flow and capital spending produced $3.25M of positive free cash flow for the period. Free cash flow represented 5.6% of revenue, linking post-investment cash generation with the company’s operating scale. Measured against total assets, free cash flow represented 3.1%, showing the cash productivity of the company’s assets.

Based on the annual report for the fiscal year ending Jun 30, 2026. Analysis generated Oct 21, 2026.